Observational studyThe Journal of infectious diseases2022
Real-World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients.
Observational study in The Journal of infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19: A rapid review and meta-analysis.Journal of medical virology · 2023Pooled it
- SARS-CoV-2 neutralizing antibody bebtelovimab - a systematic scoping review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Efficacy and safety of sotrovimab in patients with COVID-19: A rapid review and meta-analysis.Reviews in medical virology · 2022Pooled it
- Association of remdesivir treatment with long-term mortality after COVID-19 hospitalization.BMC infectious diseases · 2025Observational
- Article
- Incidence and predictors of clinical failure after early treatment for mild-to-moderate COVID-19 in high-risk individuals: A multicentric cohort study.Journal of internal medicine · 2025Article
- Article
- Development of the TSR-based computational method to investigate spike and monoclonal antibody interactions.Frontiers in chemistry · 2025Article
- A Machine Learning Method for Allocating Scarce COVID-19 Monoclonal Antibodies.JAMA health forum · 2024Article
- A guide to successful management of collaborative partnerships in quantitative research: An illustration of the science of team science.Stat (International Statistical Institute) · 2024Article
- Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ.1, BQ.1.1., and XBB.1.5 predominant omicron variants in three U.S. health systems: a retrospective cohort study.Lancet regional health. Americas · 2024Article
- Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C).Clinical drug investigation · 2024Article
- Association between monoclonal antibody therapy, vaccination, and longer-term symptom resolution after acute COVID-19.Journal of medical virology · 2024Article
- Review
- Observational
- Rapid methods for multi-level dissemination of neutralizing monoclonal antibody treatment for COVID-19 outpatients: designing for dissemination using the fit to context framework.Frontiers in public health · 2024Article
- Effectiveness of Sotrovimab in Preventing COVID-19-Related Hospitalizations or Deaths Among US Veterans During Omicron BA.1.Open forum infectious diseases · 2023Article
- Passive antibody therapy in emerging infectious diseases.Frontiers of medicine · 2023Review
- COVID-19-Omics Report: From Individual Omics Approaches to Precision Medicine.Reports (MDPI) · 2023Review
- Article
Corrections and comments
- Update of
- Update of
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundIt is not known whether sotrovimab, a neutralizing monoclonal antibody (mAb) treatment authorized for early symptomatic coronavirus disease 2019 (COVID-19) patients, is also effective in preventing the progression of severe disease and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant infection.
methodsIn an observational cohort study of nonhospitalized adult patients with SARS-CoV-2 infection, 1 October 2021-11 December 2021, using electronic health records from a statewide health system plus state-level vaccine and mortality data, we used propensity matching to select 3 patients not receiving mAbs for each patient who received outpatient sotrovimab treatment. The primary outcome was 28-day hospitalization; secondary outcomes included mortality and severity of hospitalization.
resultsOf 10 036 patients with SARS-CoV-2 infection, 522 receiving sotrovimab were matched to 1563 not receiving mAbs. Compared to mAb-untreated patients, sotrovimab treatment was associated with a 63% decrease in the odds of all-cause hospitalization (raw rate 2.1% vs 5.7%; adjusted odds ratio [aOR], 0.37; 95% confidence interval [CI], .19-.66) and an 89% decrease in the odds of all-cause 28-day mortality (raw rate 0% vs 1.0%; aOR, 0.11; 95% CI, .0-.79), and may reduce respiratory disease severity among those hospitalized.
conclusionsReal-world evidence demonstrated sotrovimab effectiveness in reducing hospitalization and all-cause 28-day mortality among COVID-19 outpatients during the Delta variant phase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.